Idiopathic Thrombocytopenic Purpura
55
2
3
41
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Published Results
19 trials with published results (35%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
3.6%
2 terminated out of 55 trials
95.3%
+8.8% vs benchmark
47%
26 trials in Phase 3/4
46%
19 of 41 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 41 completed trials
Clinical Trials (55)
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)
A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
Safety and Efficacy of Fecal Microbiota Transplantation
Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient
Investigation on a Dynamic Cohort of Italian Patients With Active ITP
Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of ICT
The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases